title: Infliximab for inpatient psoriasis management--is there a role?
abstract: BACKGROUND
  While outpatient management is a realistic goal for most psoriasis patients, inpatient hospitalization may be required for severe acute exacerbations. The paradigm of inpatient psoriasis treatment has changed as reflected in an overall decline in admissions as well as the introduction of several new agents for patients with moderate to severe disease. With these changes as well as the changes in inpatient health care delivery, the costs of inpatient psoriasis therapy need to be re-examined.
  
  
  OBJECTIVE
  To determine the mean charges and length of stay associated with inpatient admissions for psoriasis and compare these with the potential charges for infliximab administration in the inpatient setting.
  
  
  METHODS
  Inpatient psoriasis admissions were identified from the State of Maryland Health Services Cost Review Commission (HSCRC) non-confidential database from 1994 to 2003. The mean length of stay and total charges associated with psoriasis admissions were determined and adjusted to current values based upon the hospital costs component of the Consumer Price Index (CPI). The potential charges for infliximab administration were then estimated according to a presumed treatment paradigm and based on median Medicare reimbursement rates.
  
  
  RESULTS
  The mean length of stay for an inpatient psoriasis patient was 4.9 days, and the mean CPI adjusted total charges from 1994 to 2003 were $6736. In 2003, the mean total charges for a psoriasis admission were $7578. The total estimated charges for a 2-day inpatient hospitalization with infliximab administration were $6256.
  
  
  CONCLUSIONS
  Although infliximab therapy is not currently approved for psoriasis therapy it does have efficacy and may be a first-line therapy for inpatient treatment. Additionally, the high cost of infliximab may be offset by a decreased overall length of stay and its use is therefore potentially justified.
authors.affiliation: Johns Hopkins University School of Medicine, MD, USA.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Nelson
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Pearce
authors.forename: Alan B
authors.initials: AB
authors.lastname: Fleischer
authors.forename: Rajesh
authors.initials: R
authors.lastname: Balkrishnan
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000191:economics* / Q000627:therapeutic use; D017722:Hospital Charges; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D000069285:Infliximab; D011306:Prescription Fees; D011565:Psoriasis / Q000191:economics / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab